On December 19, Gelonghui reported that Aimeir Vaccine (06660.HK) announced that the group's second-generation high-efficiency adsorbed tetanus vaccine has recently obtained the "Notice of Approval for Clinical Trials" from the National Medical Products Administration, marking a new phase in the vaccine's development.

Tetanus is an extremely serious potentially fatal disease, and currently, vaccination against tetanus is the most economical and effective measure for prevention. In addition, the group is actively promoting the development of the combined vaccine (hereinafter referred to as the "quadrivalent vaccine") that separately adsorbs acellular pertussis – Hib combined vaccine and pentavalent vaccines. Among them, the quadrivalent vaccine is used to prevent whooping cough, diphtheria, tetanus, and invasive infections caused by Haemophilus influenzae type b, with advantages such as reducing the number of injections for infants and toddlers and enhancing vaccination compliance among parents and young children. Multivalent vaccines are the development trend in the Industry. According to industry consultant ZY Consulting data, it is estimated that by 2030, the domestic market scale will be about 10 billion yuan.

The development of this vaccine aligns with the group's product R&D Global Strategy layout, is an important step in achieving the group's development of multivalent products, further improves the group’s product hierarchy, enriches the group’s product line, consolidates the group’s position in the Industry, and achieves sustained high-speed growth in the group's performance.